Colorectal Cancer | Disease Landscape & Forecast | G7 | 2024
Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also benefit from EGFR inhibitors (Merck & Co. / Eli Lilly’s Erbitux and Amgen’s Vectibix), which are recommended for first-line treatment of patients with left-sided tumors. Notably, additional targeted therapies for specific molecular subtypes have been developed: immune checkpoint inhibitors (Merck & Co.’s Keytruda and Bristol Myers Squibb’s Opdivo and Yervoy) for MSI-high and/or MMR-deficient tumors; BRAF inhibitors (Array BioPharma / Pfizer’s Braftovi) for metastatic colorectal cancer with a BRAF V600E mutation; and HER2-targeted agents in some markets (Chugai’s Perjeta and trastuzumab and Seagen’s Tukysa) for HER2-positive metastatic disease. Most therapies in late-phase development are intended to treat other genomic alterations (i.e., KRAS G12C mutation) or expand the immunotherapy-based approaches for treating MSS and/or pMMR tumors.
Questions answered
- How large are the drug-treatable colorectal cancer populations? How do patient populations differ by disease stage and key biomarkers?
- What are interviewed experts’ views on current and emerging late-phase therapies, and what strategies are companies pursuing to secure uptake and share in the colorectal cancer market?
- What are the key drivers and constraints in the colorectal cancer therapy market, and how will they change over the forecast period?
Geography: United States, EU5, Japan
Primary research: 19 country-specific interviews with thought-leading medical oncologists / urologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed and recurrent incidence of colorectal cancer; drug-treatable and -treated cases by country, disease stage, tumor side, BRAF status, and RAS status
Forecast: 10-year, annualized, drug-level sales and patient share of key colorectal cancer therapies through 2033, segmented by brands / generics and epidemiological subpopulations
Drug treatments: Coverage of key current and emerging therapies
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
